Replies to post #5129 on Halozyme Therapeutics Inc (HALO)

[XenaLives]

So this is an urgent matter for Roche:

The company: Roche
Estimated worldwide sales 2012: $6.08 billion

Herceptin has long been the dominant breast cancer drug on the market. And Roche ($RHHBY) has been steadily building sales around the world. In a recent report, Decision Resources noted that overall the entire category for breast cancer therapies is likely to rise significantly for another 6 years. And with patent expiration coming in 2014 for Europe and 2018 or 2019 for the U.S.--which will open the way for biosimilars now in development--Roche has a limited window open to capitalize on the opportunity.

http://www.fiercepharma.com/special-report/herceptin-1